Page last updated: 2024-10-15

sepiapterin

Description

sepiapterin: A substrate of sepiapterin reductase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135398579
CHEMBL ID1255653
CHEBI ID194527
SCHEMBL ID258399
MeSH IDM0066927

Synonyms (59)

Synonym
MLS002153268
smr001230707
EU-0101123
lopac-s-154
NCGC00015913-01
LOPAC0_001123
17094-01-8
C00835
sepiapterin
6-lactoyl-7,8-dihydropterin
NCGC00094391-01
NCGC00094391-02
sepiapterin, solid
S-154
s(-)-2-amino-7,8-dihydro-6-(2-hydroxy-1-oxopropyl)-4(1h)-pteridione
NCGC00094391-03
l-sepiapterin
sepiapterine
4(3h)-pteridinone, 2-amino-7,8-dihydro-6-((2s)-2-hydroxy-1-oxopropyl)-
2-amino-6-[(2s)-2-hydroxypropanoyl]-7,8-dihydro-1h-pteridin-4-one
CHEBI:194527
HMS3263B07
2-amino-6-(s)-lactoyl-7,8-dihydro-4(3h)-pteridinone
cjq26ko7hp ,
sepiapterin [usan]
4(1h)-pteridinone, 2-amino-7,8-dihydro-6-(2-hydroxy-1-oxopropyl)-, (s)-
unii-cjq26ko7hp
who 11848
ptc923
ptc-923
CHEMBL1255653
cnsa-001
CCG-205198
HMS2234O10
4(3h)-pteridinone,2-amino-7,8-dihydro-6-[(2s)-2-hydroxy-1-oxopropyl]-
LP01123
SCHEMBL258399
AKOS022181294
tox21_501123
NCGC00261808-01
(s)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3h)-one
4(3h)-pteridinone, 2-amino-7,8-dihydro-6-[(2s)-2-hydroxy-1-oxopropyl]-
VPVOXUSPXFPWBN-VKHMYHEASA-N
2-amino-7,8-dihydro-6-((2s)-2-hydroxy-1-oxopropyl)-4(3h)-pteridinone
sepiapterin [inn]
2-amino-6-[(2s)-2-hydroxypropanoyl]-1,4,7,8-tetrahydropteridin-4-one
sr-01000075522
SR-01000075522-1
(s)-2-amino-7,8-dihydro-6-(2-hydroxy-1-oxopropyl)-4(1h)-pteridinone
2-amino-7,8-dihydro-6-[(2s)-2-hydroxy-1-oxopropyl]-4(1h)pteridinone
1-(2-amino-7,8-dihydro-4-hydroxy-6-pteridinyl)-2-hydroxy-1-propanone
(s)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(1h)-one
DTXSID40937902
Q2271580
SDCCGSBI-0051091.P002
NCGC00094391-05
HY-112234
CS-0044215
2-amino-6-[(2s)-2-hydroxypropanoyl]-7,8-dihydro-3h-pteridin-4-one

Research Excerpts

Overview

Sepiapterin is a main pigment component in the integument of the lemon mutant of the silkworm, Bombyx mori (L.) It is a precursor for the synthesis of tetrahydrobiopterin (BH4), which is a wellknown cofactor for aromatic amino acid hydroxylation and nitric oxide synthesis.

ExcerptReference
"Sepiapterin is a main pigment component in the integument of the lemon mutant of the silkworm, Bombyx mori (L.) (Lepidoptera: Bombycidae), and is present there in extremely high content, so lemon is a valuable genetic resource to extract sepiapterin."( Isolation, purification, and identification of an important pigment, sepiapterin, from integument of the lemon mutant of the silkworm, Bombyx mori.
Gao, J; Liu, C; Meng, Y; Wang, J; Wang, W, 2013
)
"Sepiapterin is a precursor for the synthesis of tetrahydrobiopterin (BH4), which is a wellknown cofactor for aromatic amino acid hydroxylation and nitric oxide synthesis in higher mammals. "( Optimization of Expression Conditions Enhances Production of Sepiapterin, a Precursor for Tetrahydrobiopterin Biosynthesis, in Recombinant Escherichia coli.
Jang, MH; Kim, MD; Lee, WH; Park, EH, 2015
)
"Sepiapterin (SEP) is a tetrahydrobiopterin precursor, and L-citrulline (L-Cit) is converted to endothelial nitric oxide synthase substrate, L-arginine."( Chronic Co-Administration of Sepiapterin and L-Citrulline Ameliorates Diabetic Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury in Obese Type 2 Diabetic Mice.
Baumgardt, SL; Bosnjak, ZJ; Fang, J; Ge, ZD; Kersten, JR; Leucker, TM; Paterson, M; Warltier, DC; Zhang, DX, 2016
)

Actions

ExcerptReference
"Sepiapterin reductase plays an enzymatic role in the biosynthesis of tetrahydrobiopterin, which is reported in limited studies to regulate the progression of several tumors. "( Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner.
Chen, P; Ding, J; Du, D; Du, H; Huang, X; Jiang, J; Liu, X; Lu, L; Ma, P; Peng, D; Sun, L; Wang, H; Wu, Y; Yuan, S; Zhan, M, 2020
)

Treatment

Sepiapterin treatment also reduced incidence of severe motor deficits and perinatal death following E22 hypoxia-ischemia. Sepi adapterin treatment had no effects on BH4 or guanosine triphosphate cyclohydrolase I activity. In sepiapterin-treated arteries, endothelium-dependent relaxations to calcium ionophore A23187 were significantly reduced.

ExcerptReference
"Sepiapterin treatment also reduced incidence of severe motor deficits and perinatal death following E22 hypoxia-ischemia."( Tetrahydrobiopterin in the prevention of hypertonia in hypoxic fetal brain.
Derrick, M; Ji, X; Tan, S; Vásquez-Vivar, J; Whitsett, J; Yu, L, 2009
)
"Sepiapterin treatment augmented the ICP/MAP response in all WD groups (P < 0.05)."( Erectile dysfunction precedes coronary artery endothelial dysfunction in rats fed a high-fat, high-sucrose, Western pattern diet.
Anderson, EJ; Hickner, RC; La Favor, JD; Wingard, CJ, 2013
)
"Sepiapterin treatment had no effects on BH4 or guanosine triphosphate cyclohydrolase I activity."( Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice.
Anderson, T; Pannirselvam, M; Simon, V; Triggle, CR; Verma, S, 2003
)
"In sepiapterin-treated arteries, endothelium-dependent relaxations to calcium ionophore A23187 and intracellular cGMP levels were significantly reduced."( Effect of tetrahydrobiopterin on endothelial function in canine middle cerebral arteries.
Katusic, ZS; Milstien, S; Tsutsui, M, 1996
)
"Oral treatment with sepiapterin, a tetrahydrobiopterin precursor, decreased infiltrating inflammatory cells and cytokine levels in mice with colitis."( Mitigation of Radiation-Induced Lung and Heart Injuries in Mice by Oral Sepiapterin after Irradiation.
Abbate, A; Bonaventura, A; Mauro, AG; Mezzaroma, E; Mikkelsen, RB; Rabender, CS; Yakovlev, VA, 2021
)
"Treatment with sepiapterin, which increases levels of tetrahydrobiopterin, improved vasodilation in obese mice, an improvement blocked by l-NAME."( Increasing muscle mass improves vascular function in obese (db/db) mice.
Chen, F; Fulton, DJ; Giannis, A; Han, W; Mintz, JD; Qiu, S; Salet, CD; Stepp, DW; Su, Y; Yu, Y, 2014
)
"Treatment with sepiapterin, a stable precursor of the eNOS cofactor tetrahydrobiopterin, or the nitric oxide precursor L-arginine corrected changes in eNOS dimerization and phosphorylation, corrected permeability defects, and reduced apoptosis."( Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice.
Cheng, H; Fan, X; Harris, RC; Paueksakon, P; Wang, H, 2012
)
"Pretreatment with sepiapterin induced a significant increase of cGMP level at the end of the protocol in both models."( Sepiapterin reduces postischemic injury in the rat heart.
Dietz, V; Kapitza, J; Lee, CH; Niroomand, F; Tiefenbacher, CP, 2003
)
"Pretreatment with sepiapterin, a BH4 precursor, prevented CRP-mediated effects on BH(4) levels, superoxide production as well as eNOS activity."( C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
Devaraj, S; Jialal, I; Singh, U; Vasquez-Vivar, J, 2007
)
"Pretreatment with sepiapterin, a precursor of tetrahydrobiopterin biosynthesis, increased tetrahydrobiopterin content of endothelial cells, and reduced H2O2-induced endothelial cell injury, which was measured by leakage of lactate dehydrogenase."( Reduction by tetrahydrobiopterin of H2O2-induced endothelial cell injury.
Ishii, M; Momose, K; Shimizu, S; Yamamoto, T, 1998
)
"Pretreatment with sepiapterin, a precursor of BH4, also reduced the ischemia-reperfusion injury with an increase in BH4 content in serum and stomach."( Involvement of reactive oxygen species and nitric oxide in gastric ischemia-reperfusion injury in rats: protective effect of tetrahydrobiopterin.
Ishii, M; Kiuchi, Y; Nawata, S; Shimizu, S; Yamamoto, T, 2000
)

Toxicity

ExcerptReference
" Tetrahydrobiopterin, an essential cofactor for tyrosine hydroxylase, may act as an antioxidant in dopaminergic neurones and protects against the toxic consequences of glutathione depletion."( Tetrahydrobiopterin precursor sepiapterin provides protection against neurotoxicity of 1-methyl-4-phenylpyridinium in nigral slice cultures.
Gramsbergen, JB; Hesslinger, C; Jansen, P; Madsen, JT; Meyer, M; Zimmer, J, 2003
)

Bioavailability

Spiapterin prevents LVH and dilatory remodeling after TAC by increasing the bioavailability of NO. Preincubation with sepi adapterin (10 μmol/l for 30 min) failed to improve NO(·) bioavailability in hypertensive aortas while it augmented NO( ·) production from control vessels.

ExcerptReference
" Collectively, these findings suggest that in diabetic arterioles, due to the reduced bioavailability of BH(4), the synthesis of NO by eNOS is limited, resulting in a reduced flow-induced dilation, a mechanism that may also be responsible for the development of diabetic microangiopathy and exacerbation of other vascular diseases."( Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin.
Bagi, Z; Koller, A,
)
" Loss of NO bioavailability due to reduced synthesis and increased scavenging by reactive oxygen species is a cardinal feature of endothelial dysfunction in vascular disease states."( Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease.
Alp, NJ; Channon, KM, 2004
)
" Although GTP-CH-1/BH4 levels alone do not explain the profound endothelial dysfunction seen in PPHN, increasing NO bioavailability by supplementing BH4 and quenching superoxide may prove to be therapeutically beneficial."( Developmental regulation of GTP-CH1 in the porcine lung and its relationship to pulmonary vascular relaxation.
Arrigoni, F; Haworth, S; Hislop, A; Leiper, J; Nandi, M; Vallance, P, 2006
)
" bioavailability and protect against hepatic ischemia-reperfusion (I-R) injury in type 2 diabetes mellitus."( eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling.
Champion, HC; Dugas, TR; Duranski, MR; Elrod, JW; Greer, JJ; Kevil, CG; Langston, W; Lefer, DJ; Tao, L, 2006
)
" These data suggest that eNOS uncoupling and increased nitrosylation of eNOS, decreased expressions of GTP cyclohydrolase I and sepiapterin reductase, and subsequent reduced BH4 bioavailability may be important contributors of endothelial dysfunction in aged vessels."( eNOS uncoupling and endothelial dysfunction in aged vessels.
Huang, A; Kaley, G; Sun, D; Yang, YM, 2009
)
" It is therefore likely that net BH4 cellular bioavailability reflects the balance between de novo BH4 synthesis, loss of BH4 by oxidation to BH2, and the regeneration of BH4 by DHFR."( Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease.
Channon, KM; Crabtree, MJ, 2011
)
" Levels of nitrite and nitrate (NO(x)), as an index of nitric oxide, bioavailability were significantly decreased in the iNOS(-/-) diabetic mouse heart."( Inhibition of nitric oxide synthase uncoupling by sepiapterin improves left ventricular function in streptozotocin-induced diabetic mice.
Fujita, M; Iwasaka, T; Jo, F; Jo, H; Kosaki, A; Okazaki, T; Otani, H; Shimazu, T; Yoshioka, K, 2011
)
" Previous studies showed that uncoupled endothelial nitric oxide (NO) synthase (eNOS) activity and increased NADPH oxidase activity resulted in marked decreases in NO bioavailability and impaired angiogenesis in PPHN."( Sepiapterin improves angiogenesis of pulmonary artery endothelial cells with in utero pulmonary hypertension by recoupling endothelial nitric oxide synthase.
Bakhutashvili, I; Du, J; Eis, A; Konduri, GG; Pritchard, KA; Shi, Y; Teng, RJ; Xu, H, 2011
)
" Elimination of tetrahydrobiopterin (BH(4)) and nitric oxide (NO) bioavailability may contribute to the aggravation of DN."( Advanced glycation end products-mediated hypertrophy is negatively regulated by tetrahydrobiopterin in renal tubular cells.
Chuang, LY; Guh, JY; Huang, JS; Lee, YH; Liao, YC; Shi, MD, 2012
)
" Preincubation with sepiapterin (10 μmol/l for 30 min) failed to improve NO(·) bioavailability in hypertensive aortas while it augmented NO(·) production from control vessels, implicating a hypertension-associated deficiency in sepiapterin reductase (SPR), the rate-limiting enzyme for sepiapterin conversion to H(4)B."( Endothelium-specific sepiapterin reductase deficiency in DOCA-salt hypertension.
Blair, J; Cai, H; Harrison, DG; Laude, KM; McCann, LA; Oak, JH; Wang, T; Youn, JY, 2012
)
" In order to improve NO bioavailability within the vessel wall in type-1 diabetes, we investigated treatment strategies that improve eNOS phosphorylation and NO-dependent vasorelaxation."( Enhancing eNOS activity with simultaneous inhibition of IKKβ restores vascular function in Ins2(Akita+/-) type-1 diabetic mice.
de Crom, R; Habib, SL; Janardhanan, P; Krishnan, M; Mohan, S; Natarajan, M; Reddick, RL; Roman, L; van Haperen, R, 2015
)
" These results suggest that sepiapterin prevents concentric LVH and dilatory remodeling after TAC primarily by increasing the bioavailability of NO."( Sepiapterin prevents left ventricular hypertrophy and dilatory remodeling induced by pressure overload in rats.
Fujita, M; Iwasaka, T; Otani, H; Shimazu, T; Shiojima, I; Yoshioka, K, 2015
)

Dosage Studied

ExcerptReference
" Dose-response curves were investigated in response to the endothelium-dependent agonists histamine, serotonin, and acetylcholine (for pigs, substance P) and to the endothelium-independent agonist sodium nitroprusside (SNP) under control conditions and before and after incubation of the vessels with sepiapterin (substrate for BH4 synthesis)."( Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis.
Amann, K; Bleeke, T; Kübler, W; Tiefenbacher, CP; Vahl, C; Vogt, A, 2000
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sepiapterin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (49)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency11.22020.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency28.37090.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency28.37090.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
acid sphingomyelinaseHomo sapiens (human)Potency15.848914.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency44.34050.100020.879379.4328AID488772; AID588453; AID588456
RGS12Homo sapiens (human)Potency39.81070.794310.991425.1189AID879
ATAD5 protein, partialHomo sapiens (human)Potency6.30960.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency53.17640.031637.5844354.8130AID504865; AID743255
GLS proteinHomo sapiens (human)Potency10.00000.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency25.92900.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1468
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency37.73700.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00220.540617.639296.1227AID2364; AID2528
D(1A) dopamine receptorHomo sapiens (human)Potency31.62280.02245.944922.3872AID488981
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency28.18380.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency35.48130.794321.275750.1187AID624246
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1Homo sapiens (human)Potency39.81070.794312.126325.1189AID879
importin subunit beta-1 isoform 1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
tumor susceptibility gene 101 proteinHomo sapiens (human)Potency37.28580.129810.833132.6090AID493005; AID651600
gemininHomo sapiens (human)Potency2.53490.004611.374133.4983AID624296; AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.31620.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency10.00000.00419.962528.1838AID2675
caspase-1 isoform alpha precursorHomo sapiens (human)Potency15.84890.000311.448431.6228AID900
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency8.91250.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency6.30960.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Caspase-7Homo sapiens (human)Potency12.58933.981118.585631.6228AID889
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.03010.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NPYLR7BAedes aegypti (yellow fever mosquito)EC50 (µMol)20.00000.03902.289918.3000AID1259426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (204)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (12.25)18.7374
1990's35 (17.16)18.2507
2000's72 (35.29)29.6817
2010's58 (28.43)24.3611
2020's14 (6.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.45%)5.53%
Reviews8 (3.86%)6.00%
Case Studies6 (2.90%)4.05%
Observational0 (0.00%)0.25%
Other190 (91.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]